A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401 Meeting Abstract
| Authors: | Kelly, W. K.; Halabi, S.; Carducci, M. A.; George, D. J.; Mahoney, J. F.; Stadler, W. M.; Morris, M. J.; Kantoff, P. W.; Monk, J. P. 3rd; Small, E. J.; for the Cancer and Leukemia Group B |
| Abstract Title: | A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401 |
| Meeting Title: | 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 28 |
| Issue: | 18 Suppl. |
| Meeting Dates: | 2010 Jun 4-8 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2010-06-20 |
| Start Page: | 951s |
| Language: | English |
| ACCESSION: | WOS:000208880800024 |
| DOI: | 10.1200/jco.2010.28.18_suppl.lba4511 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA4511 -- Source: Wos |
